INSM Form 144 Discloses 10,000-Share Insider Sale by Melvin Sharoky
Rhea-AI Filing Summary
Insmed, Inc. (INSM) Form 144 filing reports a proposed sale of common stock by an insider. The notice shows 10,000 shares to be sold through Merrill Lynch (Orlando address) with an aggregate market value of $1,294,600.00 and company common shares outstanding listed as 211,374,786. The securities were acquired via stock options on 05/13/2021 (5,865 shares) and 05/22/2024 (13,192 shares). A sale of 10,000 shares by Melvin Sharoky on 08/12/2025 is also reported with gross proceeds of $1,215,350.00. The filer certifies no undisclosed material adverse information. Specific filing date is not provided in the content.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider Rule 144 notice showing a small, non‑control sale; no new financial data.
The filing documents a proposed sale of 10,000 common shares by insider Melvin Sharoky under Rule 144, with the shares acquired via stock options in 2021 and 2024. The reported aggregate market value ($1.29M) and the prior sale on 08/12/2025 ($1.215M gross proceeds) are disclosed. Relative to outstanding shares (~211.4M), the amount is immaterial to capitalization and provides no operational or earnings information. This is a compliance disclosure rather than a material corporate development.
TL;DR: Disclosure meets Rule 144 mechanics; no indication of undisclosed material information.
The notice includes standard attestations about absence of undisclosed material adverse information and references potential Rule 10b5‑1 plans without specifying any plan adoption date. The filing identifies the insider, acquisition method (stock options), broker, and transaction amounts, fulfilling routine governance transparency requirements. No unusual transactions, departures, or governance actions are reported.